Table 3.
model specific decision thresholds to achieve given sensitivity or specificity for both mutation and non-mutation carriers
| Nominal specificity % | Threshold % (95% CI) | Sensitivity % | ||||
|---|---|---|---|---|---|---|
| BOADICEA | BRCAPRO | Myriad | BOADICEA | BRCAPRO | Myriad | |
| 50 | 9.2 (7.1–11) | 5.5 (3.7–8.8) | 8.6 (6.8–8.8) | 87.5 | 90.0 | 90.0 |
| 60 | 11.6 (9.4–19) | 9.4 (6.0–17) | 8.7 (8.0–11) | 85.4 | 85.4 | 90.0 |
| 70 | 22 (13–30) | 19 (11–33) | 12.2 (8.7–16) | 81.3 | 81.3 | 81.3 |
| 80 | 30 (25–39) | 35 (22–47) | 15.9 (15–16) | 70.8 | 70.8 | 62.5 |
| 90 | 46 (38–67) | 53 (39–76) | 18 (16–21) | 60.4 | 64.6 | 47.9 |
| Nominal sensitivity % | Threshold % (95% CI) | Specificity % | ||||
|---|---|---|---|---|---|---|
| BOADICEA | BRCAPRO | Myriad | BOADICEA | BRCAPRO | Myriad | |
| 50 | 67 (37–85) | 69 (51–88) | 18 (16–33) | 94.1 | 92.6 | 93.3 |
| 60 | 47.9 (29–77) | 62.0 (28–82) | 16.9 (16–21) | 90.4 | 91.9 | 88.9 |
| 70 | 30.4 (13–51) | 39.8 (13–67) | 15.9 (12–17) | 80.0 | 84.4 | 88.1 |
| 80 | 22 (5.0–32) | 26 (5.4–40) | 13 (8.7–16) | 70.4 | 75.6 | 72.6 |
| 90 | 5.0 (0.6–22) | 5.4 (0.7–25) | 8.7 (2.9–12) | 30.4 | 48.9 | 65.2 |